Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome
Purpose. Injection of anti-VEGF antibody into the vitreous body is a well-established treatment for ischemic central retinal vein occlusion (CRVO) associated macular edema. Various treatment regimens regarding the timing, number, and frequency of injections have been proposed. Methods. We reviewed t...
Saved in:
Main Authors: | Joseph Pikkel, Otzem Chassid, Yumna Busool, Ward Srour, Adi Sharabi-Nov, Itzchak Beiran |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/2013/974670 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Noncompliance with Ocular Hypertensive Treatment in Patients with Primary Open Angle Glaucoma among the Arab Population in Israel: A Cross-Sectional Descriptive Study
by: Muhannad Masoud, et al.
Published: (2013-01-01) -
Correlation between CHA2DS2-VASc Score and Glaucoma Treatment and Prognosis
by: Yoav Y. Pikkel, et al.
Published: (2018-01-01) -
Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
by: Leila El Matri, et al.
Published: (2012-01-01) -
Simultaneous Subconjunctival Triamcinolone and Bevacizumab Injections for Management of Blepharokeratoconjunctivitis in Children
by: Chu Luan Nguyen, et al.
Published: (2018-01-01) -
Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes
by: Belghmaidi Sarah, et al.
Published: (2016-01-01)